[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608333":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":29,"locations":34,"responsibleParty":91,"collaborators":28,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":28,"eligibilityCriteria":99,"healthyVolunteers":95,"sex":100,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":28,"studyType":106,"phases":107,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":37,"whyStopped":28,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"nChroma Bio","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"CRMA-1001 Part A, SAD","EXPERIMENTAL","Single ascending dose arm",[13],"Genetic: CRMA-1001",{"label":15,"type":10,"description":16,"interventionNames":17},"CRMA-1001 Part A, MAD","Multiple ascending dose arm",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"CRMA-1001 Part B","Dose expansion",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"GENETIC","CRMA-1001","Epigenetic gene silencing therapy delivered by intravenous (IV) infusion",[15,9,19],null,[30],{"name":5,"role":31,"phone":32,"phoneExt":28,"email":33},"CONTACT","(617) 915 6203","CRMA-1001-101-Study@nchromabio.com",[35,51,64,77],{"facility":36,"status":37,"city":38,"state":28,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Hospices Civils De Leon","RECRUITING","Lyon","69002","France","FR",{"type":43,"coordinates":44},"Point",[45,46],4.84789,45.74906,{"lat":46,"lon":45},[49],{"name":50,"role":31,"phone":28,"phoneExt":28,"email":28},"Fabien Zoulim",{"facility":52,"status":37,"city":53,"state":28,"zip":54,"country":53,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Queen Mary Hospital, The University of Hong Kong","Hong Kong","999077","HK",{"type":43,"coordinates":57},[58,59],114.17469,22.27832,{"lat":59,"lon":58},[62],{"name":63,"role":31,"phone":28,"phoneExt":28,"email":28},"Man Fung Yuen",{"facility":65,"status":37,"city":66,"state":28,"zip":28,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"New Zealand Clinical Research","Auckland","New Zealand","NZ",{"type":43,"coordinates":70},[71,72],174.76349,-36.84853,{"lat":72,"lon":71},[75],{"name":76,"role":31,"phone":28,"phoneExt":28,"email":28},"Edward Gane",{"facility":78,"status":37,"city":79,"state":28,"zip":80,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"King's College Hospital","London","SE5 9RS","United Kingdom","UK",{"type":43,"coordinates":84},[85,86],-0.12574,51.50853,{"lat":86,"lon":85},[89],{"name":90,"role":31,"phone":28,"phoneExt":28,"email":28},"Kaushik Agarwal",{"type":92,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100608333","phase-1-a-phase-12-open-label-single-and-multiple-ascending-dose-study-of-crma-1001-in-adults-with-chronic-hepatitis-b-100608333",false,"NCT07200193","A Phase 1\u002F2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B","A Multi-Center, Phase 1\u002F2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults With Chronic Hepatitis B","Inclusion Criteria:\n\n* Male\u002FFemale, weight 45-150 kg, age 18-64, inclusive\n* Diagnosed with Chronic Hepatitis B\n* On oral antiviral therapy\n* ALT and AST \\\u003C= 1.5 x ULN\n* Total bilirubin \\\u003C= ULN\n\nExclusion Criteria:\n\n* Significant hepatic fibrosis or cirrhosis\n* Current or prior liver disease other than HBV\n* Other protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years","64 Years",{"count":104,"type":105},66,"ESTIMATED","INTERVENTIONAL",[108,109],"PHASE1","PHASE2","This is an open-label study with single- and multiple-ascending dose arms followed by a dose expansion arm. The primary objective of the study is to determine the safety and tolerability of CRMA-1001 in adult participants with Chronic Hepatitis B. In addition, the pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of CRMA-1001 will be evaluated. CRMA-1001 is an epigenetic gene therapy delivered via intravenous (IV) infusion. Up to four dose levels will be tested. Participants will receive a single or multiple doses of CRMA-1001 and will remain on antiviral therapy during the dosing process.",[112],"Chronic Hepaititis B",[114,115,116,117,118,119],"CHB","Chronic hepatitis B","Chronic HBV","Chronic Hep B","Chronic hepatitis","HBV","2026-06-12",{"date":122,"type":123},"2026-06-15","ACTUAL",{"date":125,"type":123},"2025-12-22",{"date":127,"type":105},"2032-12-31",{"name":5,"class":6},4]